• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

作者信息

Binder Susanne

出版信息

Br J Ophthalmol. 2012 Jan;96(1):1-2. doi: 10.1136/bjophthalmol-2011-301236.

DOI:10.1136/bjophthalmol-2011-301236
PMID:22157632
Abstract
摘要

相似文献

1
Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?玻璃体内抗VEGF治疗中反应性丧失：速发耐受还是耐受性？
Br J Ophthalmol. 2012 Jan;96(1):1-2. doi: 10.1136/bjophthalmol-2011-301236.
2
Resistance, not tachyphylaxis or tolerance.是耐药性，而非快速耐受性或耐受性。
Br J Ophthalmol. 2012 Aug;96(8):1153-4. doi: 10.1136/bjophthalmol-2012-301823. Epub 2012 Apr 17.
3
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.贝伐单抗和雷珠单抗在脉络膜新生血管治疗中的快速耐受。
Br J Ophthalmol. 2012 Jan;96(1):14-20. doi: 10.1136/bjo.2011.204685. Epub 2011 Jul 26.
4
Same-day consecutive bilateral intravitreal injections of ranibizumab for the treatment of bilateral active choroidal neovascularization in age-related macular degeneration.雷珠单抗同日连续双侧玻璃体内注射治疗年龄相关性黄斑变性双侧活动性脉络膜新生血管
Acta Ophthalmol. 2012 Sep;90(6):e491-3. doi: 10.1111/j.1755-3768.2011.02327.x. Epub 2012 Jan 23.
5
Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.贝伐单抗联合曲安奈德治疗对血管内皮生长因子治疗无反应的年龄相关性黄斑变性脉络膜新生血管。
J Ocul Pharmacol Ther. 2013 May;29(4):437-41. doi: 10.1089/jop.2012.0173. Epub 2012 Dec 6.
6
Comparing ranibizumab with bevacizumab.雷珠单抗与贝伐单抗的比较。
Ophthalmology. 2011 Mar;118(3):600-600.e2. doi: 10.1016/j.ophtha.2010.10.027.
7
Bimonthly injections of ranibizumab for age-related macular degeneration.每两个月注射雷珠单抗治疗年龄相关性黄斑变性。
Graefes Arch Clin Exp Ophthalmol. 2015 May;253(5):823. doi: 10.1007/s00417-014-2877-y. Epub 2014 Dec 9.
8
Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.应用谱域光学相干断层扫描评价抗血管内皮生长因子治疗后年龄相关性黄斑变性脉络膜新生血管的变化。
Curr Eye Res. 2012 May;37(5):438-45. doi: 10.3109/02713683.2011.647227.
9
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab.抗血管内皮生长因子治疗渗出性年龄相关性黄斑变性的快速耐受性。
Br J Ophthalmol. 2012 Jan;96(1):21-3. doi: 10.1136/bjo.2011.203893. Epub 2011 Jul 6.
10
Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.在雷珠单抗治疗新生血管性年龄相关性黄斑变性期间的内皮祖细胞和血浆血管内皮生长因子及基质细胞衍生因子-1。
J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):530-8. doi: 10.1089/jop.2012.0013. Epub 2013 Apr 10.

引用本文的文献

1
Aqueous humor cytokine profile in insufficient responder to aflibercept for neovascular age-related macular degeneration.阿柏西普治疗新生血管性年龄相关性黄斑变性疗效不佳者的房水细胞因子谱
Int Ophthalmol. 2025 Aug 9;45(1):326. doi: 10.1007/s10792-025-03678-0.
2
Effect of simultaneous intravitreal ranibizumab and extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: a prospective, multicenter, and interventional open-label study.玻璃体内注射雷珠单抗与长效地塞米松联合应用对初治与难治性视网膜静脉阻塞性黄斑水肿患者的疗效：一项前瞻性、多中心、开放标签干预性研究。
Int J Ophthalmol. 2025 May 18;18(5):860-867. doi: 10.18240/ijo.2025.05.11. eCollection 2025.
3
Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases.
阿柏西普（8毫克）治疗对其他抗血管内皮生长因子药物治疗无效的玻璃体切除术后糖尿病性黄斑水肿的疗效：三例报告
Int Med Case Rep J. 2025 Apr 5;18:465-471. doi: 10.2147/IMCRJ.S512953. eCollection 2025.
4
Peptide Lv and Angiogenesis: A Newly Discovered Angiogenic Peptide.肽Lv与血管生成：一种新发现的血管生成肽。
Biomedicines. 2024 Dec 15;12(12):2851. doi: 10.3390/biomedicines12122851.
5
Evaluating the Efficacy of Conbercept and Dexamethasone Implants Sequentially in the Treatment of Refractory Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO): A One-Year Follow-Up Study.评估康柏西普与地塞米松植入剂序贯治疗视网膜中央静脉阻塞（CRVO）继发难治性黄斑水肿的疗效：一项为期一年的随访研究。
Clin Ophthalmol. 2024 Sep 30;18:2721-2730. doi: 10.2147/OPTH.S487248. eCollection 2024.
6
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration.在新生血管性年龄相关性黄斑变性的眼中，初始治疗采用阿柏西普后转换为 faricimab。
Int Ophthalmol. 2024 Sep 5;44(1):369. doi: 10.1007/s10792-024-03297-1.
7
Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes.切换至 aflibercept（3mg）治疗治疗抵抗性湿性年龄相关性黄斑变性：1 年结果。
Medicine (Baltimore). 2024 Apr 19;103(16):e37839. doi: 10.1097/MD.0000000000037839.
8
Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration.没食子酸表没食子儿茶素酯，一种支持湿性年龄相关性黄斑变性抗 VEGF 治疗的绿茶有效成分。
Nutrients. 2023 Jul 28;15(15):3358. doi: 10.3390/nu15153358.
9
Pharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases.《新生血管性眼病的药物治疗和营养补充》。
Medicina (Kaunas). 2023 Jul 20;59(7):1334. doi: 10.3390/medicina59071334.
10
Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration.新生血管性年龄相关性黄斑变性患者每月固定剂量抗血管内皮生长因子治疗的容量流体分析
Int J Ophthalmol. 2023 Jun 18;16(6):909-914. doi: 10.18240/ijo.2023.06.12. eCollection 2023.